Progress towards gene therapy for haemophilia B

International Journal of Hematology

Volumn 99, Issue 4, 2014, Pages 372-376

  Patel, Nishil ^a,b   Reiss, Ulrike ^c   Davidoff, Andrew M ^c   Nathwani, Amit C ^a,b,d  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

AAV; Gene therapy; Haemophilia

Indexed keywords

BLOOD CLOTTING FACTOR 9; PARVOVIRUS VECTOR;

ARTICLE; BLEEDING; GENE THERAPY; HEMOPHILIA B; HEPATITIS; HEPATITIS B; HUMAN; IMMUNE RESPONSE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROTEIN EXPRESSION; TREATMENT OUTCOME; ANIMAL; DEPENDOPARVOVIRUS; GENE VECTOR; GENETICS;

ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HEMOPHILIA B; HUMANS; TREATMENT OUTCOME;

EID: 84899627830     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-014-1523-0     Document Type: Article

References (23)

1. Nathwani AC, Tuddenham EG. Epidemiology of coagulation disorders. Baillieres Clin Haematol. 1992;5:383-439.
2. Ponder KP, Srivastava A. Walk a mile in the moccasins of people with haemophilia. Haemophilia. 2008;14:618-20. (Pubitemid 351638755)
3. Pipe SW. Hemophilia: new protein therapeutics. Hematology Am Soc Hematol Educ Program. 2010;2010:203-9.
4. Pipe SW. The hope and reality of long-acting hemophilia products. Am J Hematol. 2012;87(Suppl 1):S33-9.
5. Nathwani AC, Davidoff AM, Tuddenham EG. Prospects for gene therapy of haemophilia. Haemophilia. 2004;10:309-18. (Pubitemid 39077029)
6. Nakai H, Wu X, Fuess S, et al. Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol. 2005;79:3606-14. (Pubitemid 40327949)
7. Herzog RW, Hagstrom JN, Kung SH, et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA. 1997;94:5804-9. (Pubitemid 27241852)
8. Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector [see comments]. Nat Med. 1999;5:56-63. (Pubitemid 29050999)
9. Snyder RO, Miao CH, Patijn GA, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet. 1997;16:270-6. (Pubitemid 27280211)
10. Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 2003;101:2963-72. (Pubitemid 36857981)
11. Jiang H, Pierce GF, Ozelo MC, et al. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther. 2006;14:452-5. (Pubitemid 44184967)
12. Manno CS, Arruda VR, Pierce GF, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342-7. (Pubitemid 43355084)
13. Nathwani AC, Gray JT, Ng CY, et al. Self complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood. 2006;107:2653-61.
14. Nathwani AC, Gray JT, McIntosh J, et al. Safe and efficient transduction of the liver after peripheral vein infusion of self complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood. 2007;109:1414-21. (Pubitemid 46239572)
15. Thomas CE, Storm TA, Huang Z, Kay MA. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol. 2004;78:3110-22. (Pubitemid 38314369)
16. Gao GP, Alvira MR, Wang L, et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA. 2002;99:11854-9. (Pubitemid 34994488)
17. Nathwani AC, Rosales C, McIntosh J, et al. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther. 2011;19:876-85.
18. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365:2357-65.
19. Allay JA, Sleep S, Long S, et al. Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum Gene Ther. 2011;22:595-604.
20. Pien GC, Basner-Tschakarjan E, Hui DJ, et al. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J. Clin. Invest. 2009;119:1688-95.
21. Simioni P, Tormene D, Tognin G, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med. 2009;361:1671-5.
22. Finn JD, Nichols TC, Svoronos N, et al. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood. 2012;120:4521-3.
23. Mingozzi F, Anguela XM, Pavani G et al. Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med. 2013;5:194ra92.